Unraveling the genomic complexity of small-cell lung cancer

Significant clinical advances have been made in the last few years regarding lung cancer management. Molecularly targeted therapies have allowed a personalized approach for the treatment of patients with advanced non-small-cell lung cancer (NSCLC). Immunotherapy has also advanced with promising results in the treatment of several tumors, including lung cancer. Immune checkpoint inhibitors are now at the forefront of immunotherapy and two antibodies against PD-1 (nivolumab and pembrolizumab) are approved for NSCLC. Despite the significant progress that has been achieved in NSCLC, such progress is rather limited in small-cell lung cancer (SCLC).